Literature DB >> 2649094

Peptide substrates and inhibitors of the HIV-1 protease.

M L Moore1, W M Bryan, S A Fakhoury, V W Magaard, W F Huffman, B D Dayton, T D Meek, L Hyland, G B Dreyer, B W Metcalf.   

Abstract

Oligopeptides containing the consensus retroviral protease cleavage sequence Ser/Thr-X-Y-Tyr/Phe-Pro are substrates for purified recombinant HIV-1 protease with Km's in the millimolar range. The minimum sequence containing the consensus pentapeptide which serves as a good substrate is a heptapeptide spanning the P4-P3' residues. Substitution of reduced Phe-Pro or Tyr-Pro dipeptide isosteres or the statine analog 3-hydroxy-4-amino-5-phenylpentanoic acid for the scissile dipeptide afforded inhibitors of HIV-1 protease with Ki values in the micromolar range, three orders of magnitude better in affinity than the corresponding substrates. Inhibitors of HIV-1 protease may provide a novel and potentially useful therapeutic approach to the treatment of acquired immune deficiency syndrome (AIDS).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2649094     DOI: 10.1016/0006-291x(89)90008-9

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

1.  Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease.

Authors:  J Trylska; J Antosiewicz; M Geller; C N Hodge; R M Klabe; M S Head; M K Gilson
Journal:  Protein Sci       Date:  1999-01       Impact factor: 6.725

2.  Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease.

Authors:  Nancy M King; Laurence Melnick; Moses Prabu-Jeyabalan; Ellen A Nalivaika; Shiow-Shong Yang; Yun Gao; Xiaoyi Nie; Charles Zepp; Donald L Heefner; Celia A Schiffer
Journal:  Protein Sci       Date:  2002-02       Impact factor: 6.725

3.  Transition states of native and drug-resistant HIV-1 protease are the same.

Authors:  D Randal Kipp; Jennifer S Hirschi; Aya Wakata; Harris Goldstein; Vern L Schramm
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-09       Impact factor: 11.205

4.  X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor.

Authors:  A L Swain; M M Miller; J Green; D H Rich; J Schneider; S B Kent; A Wlodawer
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

5.  Flavivirus enzyme-substrate interactions studied with chimeric proteinases: identification of an intragenic locus important for substrate recognition.

Authors:  F Preugschat; E M Lenches; J H Strauss
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

6.  Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.

Authors:  Steve C Pettit; Gavin J Henderson; Celia A Schiffer; Ronald Swanstrom
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

Authors:  S C Pettit; M D Moody; R S Wehbie; A H Kaplan; P V Nantermet; C A Klein; R Swanstrom
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

8.  Development of activity assays for high-volume evaluation of human immunodeficiency virus (HIV) protease inhibitors in rat serum: results with ditekiren.

Authors:  K F Wilkinson; B D Rush; S K Sharma; D B Evans; M J Ruwart; J M Friis; M J Bohanon; P K Tomich
Journal:  Pharm Res       Date:  1993-04       Impact factor: 4.200

9.  Sensitive, hydrosoluble, macromolecular fluorogenic substrates for human immunodeficiency virus 1 proteinase.

Authors:  F Anjuère; M Monsigny; Y Lelièvre; R Mayer
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

10.  In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor.

Authors:  M J Otto; C D Reid; S Garber; P Y Lam; H Scarnati; L T Bacheler; M M Rayner; D L Winslow
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.